OPKO Health (NASDAQ:OPK) Upgraded by Wall Street Zen to Hold Rating

OPKO Health (NASDAQ:OPK) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Other analysts also recently issued research reports about the stock. Barrington Research downgraded shares of OPKO Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 29th. Weiss Ratings raised shares of OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, OPKO Health has a consensus rating of “Hold” and an average target price of $1.55.

OPKO Health Stock Down 1.4%

OPK stock opened at $1.44 on Friday. The company has a market cap of $1.09 billion, a P/E ratio of -5.33 and a beta of 1.50. OPKO Health has a 52 week low of $0.98 and a 52 week high of $1.60. The company’s 50-day moving average price is $1.21 and its 200 day moving average price is $1.25. The company has a current ratio of 3.61, a quick ratio of 3.17 and a debt-to-equity ratio of 0.28.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings data on Tuesday, April 28th. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). The firm had revenue of $124.20 million for the quarter, compared to the consensus estimate of $130.51 million. OPKO Health had a negative net margin of 36.63% and a negative return on equity of 16.78%. The firm’s revenue was down 17.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.10) earnings per share. On average, research analysts expect that OPKO Health will post -0.29 earnings per share for the current fiscal year.

Institutional Trading of OPKO Health

Several institutional investors and hedge funds have recently modified their holdings of OPK. Cubist Systematic Strategies LLC lifted its holdings in shares of OPKO Health by 2,369.9% in the first quarter. Cubist Systematic Strategies LLC now owns 119,223 shares of the biotechnology company’s stock valued at $198,000 after purchasing an additional 114,396 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of OPKO Health by 466.7% in the first quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company’s stock valued at $2,671,000 after purchasing an additional 1,324,988 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of OPKO Health by 39.2% in the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock valued at $10,602,000 after purchasing an additional 1,798,385 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of OPKO Health by 4.2% in the first quarter. Goldman Sachs Group Inc. now owns 4,001,214 shares of the biotechnology company’s stock valued at $6,642,000 after purchasing an additional 161,394 shares in the last quarter. Finally, Caxton Associates LLP purchased a new stake in shares of OPKO Health in the first quarter valued at about $130,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.